Enochian announces scientific presentation of proof-of-concept studies

Enochian BioSciences announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles. The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company’s proprietary technology combining cell-, gene- and immunotherapy. Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act. The results were part of an invited plenary lecture delivered by Dr. Jewett at the 8th Annual Innate Killer Summit in San Diego, California. "We are very excited by the promising results from the proof-of-concept studies conducted by Dr. Jewett and her colleagues at UCLA," said Dr. Mark Dybul, CEO of the Company.